Thalidomide and Dexamethasone Induction Therapy Until Best Response in Recently Diagnosed Patients with Multiple Myeloma: Results From a Pilot Study
Document title: Thalidomide and Dexamethasone Induction Therapy Until Best Response in Recently Diagnosed Patients with Multiple Myeloma: Results From a Pilot Study
Journal: Revista de investigación clínica
Database: PERIÓDICA
System number: 000389659
ISSN: 0034-8376
Authors: 1
2
2
2
2
Institutions: 1Instituto Mexicano del Seguro Social, Hospital Regional de Alta Especialidad, León, Guanajuato. México
2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Hematología y Oncología, Tlalpan, Distrito Federal. México
Year:
Season: Sep-Oct
Volumen: 67
Number: 5
Pages: 304-312
Country: México
Language: Inglés
Document type: Estadística o encuesta
Approach: Caso clínico, analítico
English abstract Novel therapies for multiple myeloma are not affordable for all healthcare systems. Objectives: The objectives of this study were to evaluate the response rates, overall survival, event-free survival, and toxicity of thalidomide and dexamethasone administered until best response in recently diagnosed patients with multiple myeloma. Methods: All recently diagnosed multiple myeloma patients meeting the inclusion criteria received the same treatment with thalidomide and dexamethasone. Results: We studied 28 patients. Overall response rate was 75%. Complete response, partial response, and very good partial response were 25.0, 32.1, and 17.9%, respectively. The most frequent adverse event related to therapy was neuropathy. Median overall survival was 66 months, and median event-free survival was 39 months (range, 27.6-50.4). Variables that negatively affected overall survival on multivariate analysis included the presence of extramedullary disease, t(14;16), and chromosome 13 deletion. Conclusions: Induction therapy with thalidomide and dexamethasone until obtaining the best response in patients with recently diagnosed multiple myeloma was a useful and safe strategy. It represents an alternative for patients with limited access to costly drugs
Disciplines: Medicina
Keyword: Oncología,
Terapéutica y rehabilitación,
Mieloma múltiple,
Talidomida,
Dexametasona,
Eventos adversos,
Sobrevivencia
Keyword: Medicine,
Oncology,
Therapeutics and rehabilitation,
Multiple myeloma,
Thalidomide,
Dexamethasone,
Adverse effects,
Survival
Full text: Texto completo (Ver PDF)